Antimicrobial screening of new 5-(chromene-3-yl)methylene-2,4-thiazolidinediones

Nastasă, Cristina; Duma, Mihaela; Tiperciuc, Brîndușa; Oniga, Ovidiu

doi:10.3329/bjp.v10i3.24401

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on our previous experience in the synthesis of new bioactive compounds bearing the thiazolidine-2,4-dione heterocycle as an important scaffold in medicinal chemistry [12][13][14], in the present study, we present the synthesis of a new 5-chromenyl-methylene-thiazolidine-2,4-dione derivative (TZDd). Further, we evaluated its effect on the oxidative stress in streptozotocin (STZ)-induced diabetic rats.…”

Section: Introductionmentioning

confidence: 99%

"The effects of a new chromenyl-methylenethiazolidine-2,4-dione in alleviating oxidative stress in a rat model of streptozotocin induced diabetes "

Chis¹,

Clichici²,

Simedrea³

et al. 2018

Studia UBB Chemia

Self Cite

View full text Add to dashboard Cite

Type 1 diabetes mellitus (T1DM) is caused by the insulin deficiency resulting from the progressive destruction of pancreatic β cells. Thiazolidine-2,4-diones (TZDs) activate the peroxisome proliferator-activated receptor-γ (PPARγ) and enhance the actions of insulin. 5-((6-methyl-4-oxo-4Hchromen-3-yl)methylene)-3-(2-(4-nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (TZDd) is a heterocyclic derivative synthesized in our laboratory. The purpose of this study was to examine whether TZDd has hypoglycemic and antioxidant effects in diabetic rats. Its effects were compared with those of quercetin (Que), a potent antioxidant, and with pioglitazone (Pio), a well-known antidiabetic drug. Type 1 DM was induced in Wistar rats by the intraperitoneal administration of streptozotocin (STZ) (60 mg/kg). The non-diabetic and diabetic rats were treated with Que (30 mg/kg/day), pioglitazone (30 mg/kg/day), or TZDd (30 mg/kg/day), for 5 weeks. The serum levels of malondialdehyde (MDA) and protein carbonyl (PC) groups, and the superoxide dismutase (SOD) and catalase (CAT) activities in the blood were then assessed. The results indicated that the TZDd decreased the blood oxidative stress parameters in the treated diabetic rats, compared to Que and pioglitazone. In conclusion, the hypoglycemic and antioxidant effects of TZDd in diabetic rats, suggest its therapeutic properties for the clinical treatment of T1DM.

show abstract

Section: Introductionmentioning

confidence: 99%